The Impact of Grapefruit Juice on the Response to Clopidogrel
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study will measure the percentage of platelet aggregation inhibition with a loading dose of clopidogrel (300 mg) using the VerifyNow Assay System in healthy volunteers who have drank 11 oz of grapefruit juice. It will also measure the percentage of platelet aggregation inhibition with a maintenance dose of clopidogrel (75 mg/day) using the VerifyNow Assay System in healthy volunteers who have drank 11 oz grapefruit juice daily.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Dietary Supplement: Grapefruit juice Drug: Clopidogrel 75 mg/day Drug: Clopidogrel 300 mg |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Screening |
| Official Title: | The Impact of Grapefruit Juice on the Response to a Loading Dose and Maintenance Dose of Clopidogrel in Healthy Volunteers |
- % Platelet Inhibition [ Time Frame: 6 hours ] [ Designated as safety issue: No ]% platelet inhibition measured by Verify Now
| Enrollment: | 32 |
| Study Start Date: | November 2008 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Loading Dose
Participants received a 300 mg dose of clopidogrel with or without GFJ.
|
Dietary Supplement: Grapefruit juice
Participants received grapefruit juice during 1 of the 2 periods.
Drug: Clopidogrel 300 mg
|
|
Experimental: Maintenance Dose
Participants received clopidogrel 75 mg/day for 7 days with or without GFJ
|
Dietary Supplement: Grapefruit juice
Participants received grapefruit juice during 1 of the 2 periods.
Drug: Clopidogrel 75 mg/day
|
Detailed Description:
This study will examine the effect of GFJ on the loading dose (300 mg) of clopidogrel and will evaluate the effect of GFJ on the maintenance dose (75 mg/day) of clopidogrel. Subjects will be randomized to either initially receive GFJ prior to their loading dose of clopidogrel or receive GFJ prior to their second loading dose. The subjects who have been randomized to receive GFJ initially will drink two small cans (11 oz total) of regular strength GFJ in the morning, followed two hours later by a loading dose (300 mg) of clopidogrel and will then return to the clinic 6 hours after their loading dose to have their platelet inhibition measured. Subjects will have ~ 5 milliliters (1 teaspoonful) of whole blood drawn from an antecubital vein in their forearm via a 21 gauge needle attached to a blue-top plastic vacuette sodium citrate blood collection (Greiner, Monroe, NC) tube to test inhibition of platelet aggregation. After their first loading dose, a 2 week washout period will follow to allow for their platelet aggregation to return to normal. Following the washout period, the subjects will take their second loading dose of clopidogrel and again return to the clinic for platelet inhibition measurement. The same timing will be followed for the loading dose taken without prior GFJ.
During the maintenance dose phase of this study, subjects will take 75 mg/day clopidogrel for 7 days with or without GFJ. Subjects will be randomized to either GFJ during the first period or GFJ during the second period. A minimum 2 week washout period will occur between the two 7 day courses of clopidogrel. Platelet inhibition measurement will occur at the end of each 7 day period as described above.
Eligibility| Ages Eligible for Study: | 19 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Ages 19-40
- Health status confirmed by medical history and physical examination and laboratory analysis
Exclusion Criteria:
- Pregnancy
- Taking routine prescription or over-the-counter prescriptions
- Taken over-the-counter analgesic/anti-inflammatory medication within two weeks of study participation
- Recently had grapefruit juice or regularly drinks grapefruit juice
Contacts and Locations| United States, Nebraska | |
| Creighton Cardiac Center | |
| Omaha, Nebraska, United States, 68131 | |
| Principal Investigator: | Tammy Burns, PharmD | Creighton Cardiac Center |
More Information
No publications provided
| Responsible Party: | Creighton University |
| ClinicalTrials.gov Identifier: | NCT00817999 History of Changes |
| Other Study ID Numbers: | 08-15073 |
| Study First Received: | January 6, 2009 |
| Results First Received: | August 8, 2011 |
| Last Updated: | August 28, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Creighton University:
|
Platelet Aggregation Inhibition |
Additional relevant MeSH terms:
|
Clopidogrel Ticlopidine Platelet Aggregation Inhibitors Hematologic Agents Therapeutic Uses Pharmacologic Actions Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists |
Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Fibrinolytic Agents Fibrin Modulating Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 19, 2013